Dr. Margolin has more than 35 years of experience in the venture capital, pharmaceutical and biotech industries. As a senior manager, skilled scientist and experienced board member, she possesses a highly developed combination of leadership, decision-making and business skills. Dr. Margolin has served as president & CEO of Gamida Cell since 2005. During this time, she has led Gamida Cell from pre-clinical development through phase 3 international registration studies, the receipt of a Breakthrough Therapy Designation for the company’s lead product, strategic collaborations and the raising of $100 million from various financing initiatives. Dr. Margolin previously served as vice president of Denali Ventures LLC, a healthcare specialized venture capital firm, and a program manager at Teva Pharmaceuticals, leading multiple drug development programs. Dr. Margolin holds a Ph.D. in Biology from the Weizmann Institute of Science and was a post-doctoral associate at the Yale University School of Medicine.
Tony Peled is the co-founder of the company and the researcher whose discoveries have led to Gamida Cell’s key clinical achievements, which are supported by many patents. Until today, Dr. Peled continues to lead the development of Gamida Cell’s next generation novel technologies and pipeline of products. Prior to founding Gamida Cell, she was a scientist at the Hematology Department, Hadassah University Hospital, Jerusalem, Israel and has more than 15 years of experience in hematopoiesis and stem cell research.
Dr. Simantov has more than 20 years of experience in research, development, registration, and launch of hematology and oncology drugs. She is the former VP and Head of Global Medical Affairs at Pfizer Oncology. Dr. Simantov earned a B.A. from Johns Hopkins University and an M.D. from New York University School of Medicine. She is based in New York.
Naftali Brikashvili has more than 15 years of experience in all aspects of accounting and finance. He is responsible for all the financial aspects of Gamida Cell. Prior to joining the company in April 2000, Mr. Brikashvili served as the finance manager at Donna Engineering Construction and Mertens Hoffman Software & Logistics. He has a B.A. in accounting & economics from the Hebrew University, Jerusalem and an LLM degree from Bar Ilan University. Mr. Brikashvili earned his CPA license in 1996.
Ms. Harati has 28 years of experience in the pharmaceutical and biotechnology industries. Ms. Harati is responsible for quality assurance as well as technology transfer and manufacturing at Gamida Cell and at the different CMOs. She is also credited with building a logistics system, especially built for Gamida Cell’s requirements. Prior to joining Gamida Cell, Ms. Harati served as the director of the quality control laboratories at Perio Products Ltd., a pharmaceutical company specialized in manufacturing innovative drugs. While at Perio Products she implemented quality systems in accordance with FDA requirements and European regulations. Her primary expertise is in building and developing quality from the first steps of product development to marketing.
Dr. Snyder has worked on the senior management teams of international pharmaceutical and biotechnology companies in the US and in Israel. Dr. Snyder is highly experienced in the design and management of clinical strategies and protocols as well as the supervision of sponsor interactions with the regulatory agencies in these areas. His focus for nearly the last fifteen years has been advising and directing high-level communications with opinion leaders, consultants and regulatory agencies in the field of cellular therapies. Dr. Snyder earned a Ph.D. in medical biochemistry from the Hebrew University in Jerusalem and performed his post-doctoral work in neurobiology at Duke University.